Excessive HIF-1α driven by phospholipid metabolism causes septic cardiomyopathy through cytopathic hypoxia.

Summary

This mechanistic study shows that LPS enhances phospholipid metabolism to drive excessive cardiomyocyte HIF-1α, which suppresses mitochondrial respiration via iNOS/NO and causes cytopathic hypoxia, leading to septic cardiomyopathy. Cardiac HIF-1α haploinsufficiency and inhibition of COX2/sPLA2 attenuated mitochondrial and contractile dysfunction, implicating prostaglandins and lysophospholipids via PKA in stabilizing HIF-1α.

Key Findings

• LPS upregulates cardiomyocyte HIF-1α, suppressing mitochondrial respiration via iNOS-dependent nitric oxide and causing cytopathic hypoxia.
• Cardiac-specific HIF-1α haploinsufficiency ameliorates mitochondrial and contractile dysfunction in a mouse model of septic cardiomyopathy.
• NF-κB–driven COX2 and sPLA2 upregulation increases HIF-1α; their inhibition prevents HIF-1α induction, cytopathic hypoxia, and dysfunction.
• Phospholipid metabolites (prostaglandins, lysophospholipids/free fatty acids) stabilize HIF-1α via PKA activation.

Clinical Implications

While preclinical, the work supports testing COX2/sPLA2/PKA modulation or HIF-1α/iNOS attenuation strategies to prevent or treat septic cardiomyopathy, and motivates biomarker development around lipid mediators and HIF-1α activity.

Limitations

• Mouse LPS model may not capture full heterogeneity of human septic cardiomyopathy.
• Lack of validation in human cardiac tissue or clinical cohorts.

Future Directions

Evaluate COX2/sPLA2/PKA or HIF-1α/iNOS modulation in clinically relevant sepsis models and explore translational biomarkers and early-phase trials in septic patients with myocardial dysfunction.